Analysis
Website
iDEL Therapeutics
Analysis
Website
iDEL Therapeutics
Analysis
Website
iDEL Therapeutics
Summary
About
Company
iDEL Therapeutics
Overall Score of Website
24
Analysed on 2026-03-20
Description
iDEL Therapeutics is a Dortmund-based oncology biotech startup founded in 2025 by Dr. Marcus Kostka (CEO, serial biotech entrepreneur — Abalos Therapeutics Phase I, MODAG/Teva partnership), Dr. Andreas Briel (Scientific co-founder, nanopet pharma, Berlin contrast agent research origin), and Dr. Jürgen Moll. Technology: synthetic shuttle platform for direct cytosolic drug delivery into tumour cells — evades endosomal trapping, compatible with large and small molecules (nanobodies, cytotoxic payloads, siRNA). Two lead programs: (1) sdAb targeting intracellular oncotarget — significant tumour shrinkage in preclinical in vivo models; (2) multi-cancer drug conjugate (no tumour-associated antigen required). Funding: €9M seed (March 17, 2026, announced 3 days ago), led by BiomedVC (Swiss early-stage biotech VC); co-investors: NRW.Venture (€3.5M, NRW.BANK), Gründerfonds Ruhr, KHAN Technology Transfer Fund II (Max Planck Foundation, European Investment Fund backing). Website: idel-therapeutics.com (submitted) vs idel-tx.com (referenced in press release).
Market
Oncology Drug Delivery / Intracellular Therapeutics / Biotech / Cancer Drug Conjugates
Audience
Oncology pharma business development teams, European biotech investors, academic medical oncology researchers, drug delivery technology platform evaluators
HQ
Dortmund, Germany (Biomedizin Zentrum)
Summary
Spider Chart
Freshness
8
Brand
15
Content
20
Strategy
22
Social Proof
25
SEO
18
Content
28
Navigation
30
Content
35
Brand
38
Freshness
€9M Seed Financing Announced March 17, 2026 — 3 Days Ago — Site Cannot Be Fetched, Likely Just Launched
Score
8
Severity
Critical
Finding
iDEL Therapeutics announced its €9M seed round on March 17, 2026 — 3 days before this audit. The round was led by BiomedVC (Swiss early-stage biotech VC) with NRW.Venture (€3.5M), Gründerfonds Ruhr, and KHAN Technology Transfer Fund II. The company was founded in 2025 and the announcement simultaneously established the leadership team publicly. The press release notes 'Find more information at www.idel-tx.com' — not idel-therapeutics.com — suggesting the submitted URL may be a redirect or the website is at a different primary domain.
Recommendation
Clarify the canonical domain: is idel-therapeutics.com the primary website or a redirect to idel-tx.com? The press release consistently references idel-tx.com. Ensure that idel-therapeutics.com 301-redirects to idel-tx.com with a clear canonical tag, so all press links (GlobeNewswire, BioSpace, EU-Startups) that reference either domain pass SEO authority to the primary site.
Freshness
€9M Seed Financing Announced March 17, 2026 — 3 Days Ago — Site Cannot Be Fetched, Likely Just Launched
Score
8
Severity
Critical
Finding
iDEL Therapeutics announced its €9M seed round on March 17, 2026 — 3 days before this audit. The round was led by BiomedVC (Swiss early-stage biotech VC) with NRW.Venture (€3.5M), Gründerfonds Ruhr, and KHAN Technology Transfer Fund II. The company was founded in 2025 and the announcement simultaneously established the leadership team publicly. The press release notes 'Find more information at www.idel-tx.com' — not idel-therapeutics.com — suggesting the submitted URL may be a redirect or the website is at a different primary domain.
Recommendation
Clarify the canonical domain: is idel-therapeutics.com the primary website or a redirect to idel-tx.com? The press release consistently references idel-tx.com. Ensure that idel-therapeutics.com 301-redirects to idel-tx.com with a clear canonical tag, so all press links (GlobeNewswire, BioSpace, EU-Startups) that reference either domain pass SEO authority to the primary site.
Freshness
€9M Seed Financing Announced March 17, 2026 — 3 Days Ago — Site Cannot Be Fetched, Likely Just Launched
Score
8
Severity
Critical
Finding
iDEL Therapeutics announced its €9M seed round on March 17, 2026 — 3 days before this audit. The round was led by BiomedVC (Swiss early-stage biotech VC) with NRW.Venture (€3.5M), Gründerfonds Ruhr, and KHAN Technology Transfer Fund II. The company was founded in 2025 and the announcement simultaneously established the leadership team publicly. The press release notes 'Find more information at www.idel-tx.com' — not idel-therapeutics.com — suggesting the submitted URL may be a redirect or the website is at a different primary domain.
Recommendation
Clarify the canonical domain: is idel-therapeutics.com the primary website or a redirect to idel-tx.com? The press release consistently references idel-tx.com. Ensure that idel-therapeutics.com 301-redirects to idel-tx.com with a clear canonical tag, so all press links (GlobeNewswire, BioSpace, EU-Startups) that reference either domain pass SEO authority to the primary site.
Brand
idel-tx.com vs idel-therapeutics.com — Press Release Uses idel-tx.com But Submitted URL Is idel-therapeutics.com
Score
15
Severity
High
Finding
The BioSpace press release explicitly states: 'Find more information at www.idel-tx.com.' The EU-Startups, GlobeNewswire, and VC Magazin coverage all link to the press release. If idel-therapeutics.com is a different domain from idel-tx.com, the company has a split web presence on launch day — which distributes the SEO benefit of the press cycle across two URLs.
Recommendation
Establish idel-tx.com as the canonical primary domain (shorter, more memorable, already referenced in all press materials) and implement a permanent 301 redirect from idel-therapeutics.com → idel-tx.com. Or vice versa if idel-therapeutics.com is preferred for professional/clinical contexts. The key is that all press links should resolve to one domain so that Google consolidates the Domain Authority from the launch coverage onto a single entity.
Brand
idel-tx.com vs idel-therapeutics.com — Press Release Uses idel-tx.com But Submitted URL Is idel-therapeutics.com
Score
15
Severity
High
Finding
The BioSpace press release explicitly states: 'Find more information at www.idel-tx.com.' The EU-Startups, GlobeNewswire, and VC Magazin coverage all link to the press release. If idel-therapeutics.com is a different domain from idel-tx.com, the company has a split web presence on launch day — which distributes the SEO benefit of the press cycle across two URLs.
Recommendation
Establish idel-tx.com as the canonical primary domain (shorter, more memorable, already referenced in all press materials) and implement a permanent 301 redirect from idel-therapeutics.com → idel-tx.com. Or vice versa if idel-therapeutics.com is preferred for professional/clinical contexts. The key is that all press links should resolve to one domain so that Google consolidates the Domain Authority from the launch coverage onto a single entity.
Brand
idel-tx.com vs idel-therapeutics.com — Press Release Uses idel-tx.com But Submitted URL Is idel-therapeutics.com
Score
15
Severity
High
Finding
The BioSpace press release explicitly states: 'Find more information at www.idel-tx.com.' The EU-Startups, GlobeNewswire, and VC Magazin coverage all link to the press release. If idel-therapeutics.com is a different domain from idel-tx.com, the company has a split web presence on launch day — which distributes the SEO benefit of the press cycle across two URLs.
Recommendation
Establish idel-tx.com as the canonical primary domain (shorter, more memorable, already referenced in all press materials) and implement a permanent 301 redirect from idel-therapeutics.com → idel-tx.com. Or vice versa if idel-therapeutics.com is preferred for professional/clinical contexts. The key is that all press links should resolve to one domain so that Google consolidates the Domain Authority from the launch coverage onto a single entity.
Content
Endosomal Trapping' — Core Technology Requires Plain-Language Explanation for Non-Specialist Investors
Score
20
Severity
High
Finding
The core scientific challenge iDEL solves — endosomal trapping — is a technical barrier that requires explanation for the non-oncology-expert investor, journalist, or pharma business development contact. Coverage from EU-Startups describes it as: 'large molecules such as antibodies are often trapped in endosomes and subsequently degraded.' The European Biotechnology Magazine article provides the clearest plain-language analogy: the technology is like a 'wonder shuttle' that bypasses the cell's waste disposal system.
Recommendation
Add a plain-language explainer to the homepage: 'Most cancer drugs can't reach their targets inside tumour cells — they get trapped and destroyed before they get there. iDEL's shuttle technology bypasses this barrier, delivering drug payloads directly into the cytosol where cancer targets live. Compatible with antibodies, small molecules, and nanobodies — against the hardest-to-drug targets in oncology.' This three-sentence explanation makes the science accessible without dumbing it down.
Content
Endosomal Trapping' — Core Technology Requires Plain-Language Explanation for Non-Specialist Investors
Score
20
Severity
High
Finding
The core scientific challenge iDEL solves — endosomal trapping — is a technical barrier that requires explanation for the non-oncology-expert investor, journalist, or pharma business development contact. Coverage from EU-Startups describes it as: 'large molecules such as antibodies are often trapped in endosomes and subsequently degraded.' The European Biotechnology Magazine article provides the clearest plain-language analogy: the technology is like a 'wonder shuttle' that bypasses the cell's waste disposal system.
Recommendation
Add a plain-language explainer to the homepage: 'Most cancer drugs can't reach their targets inside tumour cells — they get trapped and destroyed before they get there. iDEL's shuttle technology bypasses this barrier, delivering drug payloads directly into the cytosol where cancer targets live. Compatible with antibodies, small molecules, and nanobodies — against the hardest-to-drug targets in oncology.' This three-sentence explanation makes the science accessible without dumbing it down.
Content
Endosomal Trapping' — Core Technology Requires Plain-Language Explanation for Non-Specialist Investors
Score
20
Severity
High
Finding
The core scientific challenge iDEL solves — endosomal trapping — is a technical barrier that requires explanation for the non-oncology-expert investor, journalist, or pharma business development contact. Coverage from EU-Startups describes it as: 'large molecules such as antibodies are often trapped in endosomes and subsequently degraded.' The European Biotechnology Magazine article provides the clearest plain-language analogy: the technology is like a 'wonder shuttle' that bypasses the cell's waste disposal system.
Recommendation
Add a plain-language explainer to the homepage: 'Most cancer drugs can't reach their targets inside tumour cells — they get trapped and destroyed before they get there. iDEL's shuttle technology bypasses this barrier, delivering drug payloads directly into the cytosol where cancer targets live. Compatible with antibodies, small molecules, and nanobodies — against the hardest-to-drug targets in oncology.' This three-sentence explanation makes the science accessible without dumbing it down.
Strategy
Two Lead Programs Towards Clinical Evaluation — Program Names Not Public
Score
22
Severity
High
Finding
Press releases confirm 'two proprietary lead programs towards clinical evaluation' — a single-domain antibody (sdAb) programme against an intracellular oncotarget (significant tumour shrinkage observed in preclinical models) and a multi-cancer drug conjugate approach (no tumour-associated antigen required). Neither programme has a public name, indication, or target disclosed. For a company that is both raising capital and seeking pharmaceutical partnership deals, disclosed programme names anchor investor and BD conversations.
Recommendation
At minimum, assign internal code names to the two lead programmes (e.g., IDL-001 and IDL-002) and publish them on the pipeline page: 'IDL-001: Single-domain antibody targeting [class of intracellular oncotarget] · Preclinical: significant tumour shrinkage observed · IND-enabling studies 2027 (estimated). IDL-002: Multi-cancer drug conjugate · Pan-tumour applicability · Preclinical.' Pharma BD teams and biotech investors expect this level of disclosure from a company seeking seed capital and clinical partnerships.
Strategy
Two Lead Programs Towards Clinical Evaluation — Program Names Not Public
Score
22
Severity
High
Finding
Press releases confirm 'two proprietary lead programs towards clinical evaluation' — a single-domain antibody (sdAb) programme against an intracellular oncotarget (significant tumour shrinkage observed in preclinical models) and a multi-cancer drug conjugate approach (no tumour-associated antigen required). Neither programme has a public name, indication, or target disclosed. For a company that is both raising capital and seeking pharmaceutical partnership deals, disclosed programme names anchor investor and BD conversations.
Recommendation
At minimum, assign internal code names to the two lead programmes (e.g., IDL-001 and IDL-002) and publish them on the pipeline page: 'IDL-001: Single-domain antibody targeting [class of intracellular oncotarget] · Preclinical: significant tumour shrinkage observed · IND-enabling studies 2027 (estimated). IDL-002: Multi-cancer drug conjugate · Pan-tumour applicability · Preclinical.' Pharma BD teams and biotech investors expect this level of disclosure from a company seeking seed capital and clinical partnerships.
Strategy
Two Lead Programs Towards Clinical Evaluation — Program Names Not Public
Score
22
Severity
High
Finding
Press releases confirm 'two proprietary lead programs towards clinical evaluation' — a single-domain antibody (sdAb) programme against an intracellular oncotarget (significant tumour shrinkage observed in preclinical models) and a multi-cancer drug conjugate approach (no tumour-associated antigen required). Neither programme has a public name, indication, or target disclosed. For a company that is both raising capital and seeking pharmaceutical partnership deals, disclosed programme names anchor investor and BD conversations.
Recommendation
At minimum, assign internal code names to the two lead programmes (e.g., IDL-001 and IDL-002) and publish them on the pipeline page: 'IDL-001: Single-domain antibody targeting [class of intracellular oncotarget] · Preclinical: significant tumour shrinkage observed · IND-enabling studies 2027 (estimated). IDL-002: Multi-cancer drug conjugate · Pan-tumour applicability · Preclinical.' Pharma BD teams and biotech investors expect this level of disclosure from a company seeking seed capital and clinical partnerships.
Social Proof
Marcus Kostka Serial Biotech Builder (Abalos Therapeutics Clinical I, MODAG/Teva Partnership) — Founder Credibility Not Prominent
Score
25
Severity
Medium
Finding
Co-founder Marcus Kostka (CEO) has a track record that is unusual for a seed-stage company: he helped translate Abalos Therapeutics from early discovery to clinical Phase I and guided MODAG (Parkinson's drug development) to a Teva partnership. This is the exact 'translation capability' — bridging scientific discovery and pharma investment — that validates the team's ability to execute on iDEL's clinical roadmap. European Biotechnology Magazine notes his role explicitly: 'My focus is to bring the right people together to get the translation of an exciting discovery done.'
Recommendation
Feature Kostka's track record prominently in the Leadership/About section: 'CEO Marcus Kostka, PhD — Serial biotech entrepreneur · Abalos Therapeutics (Phase I clinical) · MODAG (Teva partnership) · Serial Entrepreneurs and industry experts.' The combination of his translation track record and the NRW.Venture/BiomedVC investor network (confirmed to have 'gathered again' around him at iDEL) signals that this team has done this before and knows how to execute.
Social Proof
Marcus Kostka Serial Biotech Builder (Abalos Therapeutics Clinical I, MODAG/Teva Partnership) — Founder Credibility Not Prominent
Score
25
Severity
Medium
Finding
Co-founder Marcus Kostka (CEO) has a track record that is unusual for a seed-stage company: he helped translate Abalos Therapeutics from early discovery to clinical Phase I and guided MODAG (Parkinson's drug development) to a Teva partnership. This is the exact 'translation capability' — bridging scientific discovery and pharma investment — that validates the team's ability to execute on iDEL's clinical roadmap. European Biotechnology Magazine notes his role explicitly: 'My focus is to bring the right people together to get the translation of an exciting discovery done.'
Recommendation
Feature Kostka's track record prominently in the Leadership/About section: 'CEO Marcus Kostka, PhD — Serial biotech entrepreneur · Abalos Therapeutics (Phase I clinical) · MODAG (Teva partnership) · Serial Entrepreneurs and industry experts.' The combination of his translation track record and the NRW.Venture/BiomedVC investor network (confirmed to have 'gathered again' around him at iDEL) signals that this team has done this before and knows how to execute.
Social Proof
Marcus Kostka Serial Biotech Builder (Abalos Therapeutics Clinical I, MODAG/Teva Partnership) — Founder Credibility Not Prominent
Score
25
Severity
Medium
Finding
Co-founder Marcus Kostka (CEO) has a track record that is unusual for a seed-stage company: he helped translate Abalos Therapeutics from early discovery to clinical Phase I and guided MODAG (Parkinson's drug development) to a Teva partnership. This is the exact 'translation capability' — bridging scientific discovery and pharma investment — that validates the team's ability to execute on iDEL's clinical roadmap. European Biotechnology Magazine notes his role explicitly: 'My focus is to bring the right people together to get the translation of an exciting discovery done.'
Recommendation
Feature Kostka's track record prominently in the Leadership/About section: 'CEO Marcus Kostka, PhD — Serial biotech entrepreneur · Abalos Therapeutics (Phase I clinical) · MODAG (Teva partnership) · Serial Entrepreneurs and industry experts.' The combination of his translation track record and the NRW.Venture/BiomedVC investor network (confirmed to have 'gathered again' around him at iDEL) signals that this team has done this before and knows how to execute.
SEO
Launch-Day SEO — GlobeNewswire/BioSpace Press Release Links — All Point to idel-tx.com Not idel-therapeutics.com
Score
18
Severity
High
Finding
The GlobeNewswire press release (the primary syndication vehicle for the announcement) links to idel-tx.com. BioSpace, EU-Startups, and VC Magazin all follow the press release. This means all SEO authority from the launch press cycle flows to idel-tx.com — not idel-therapeutics.com. If idel-therapeutics.com is not configured to receive this authority via a proper redirect or canonical tag, the submitted URL is receiving zero SEO benefit from the announcement.
Recommendation
Implement a 301 permanent redirect from idel-therapeutics.com → idel-tx.com today. Then set the page title at idel-tx.com: 'iDEL Therapeutics — Direct Cytosolic Drug Delivery for Oncology | Dortmund, Germany.' Meta description: 'iDEL Therapeutics delivers drugs directly into the cytosol of tumour cells using proprietary shuttle technology — unlocking historically undruggable intracellular targets. Two lead oncology programs advancing to clinic. €9M funded by BiomedVC and NRW.Venture.' Submit the sitemap to Google Search Console on launch day.
SEO
Launch-Day SEO — GlobeNewswire/BioSpace Press Release Links — All Point to idel-tx.com Not idel-therapeutics.com
Score
18
Severity
High
Finding
The GlobeNewswire press release (the primary syndication vehicle for the announcement) links to idel-tx.com. BioSpace, EU-Startups, and VC Magazin all follow the press release. This means all SEO authority from the launch press cycle flows to idel-tx.com — not idel-therapeutics.com. If idel-therapeutics.com is not configured to receive this authority via a proper redirect or canonical tag, the submitted URL is receiving zero SEO benefit from the announcement.
Recommendation
Implement a 301 permanent redirect from idel-therapeutics.com → idel-tx.com today. Then set the page title at idel-tx.com: 'iDEL Therapeutics — Direct Cytosolic Drug Delivery for Oncology | Dortmund, Germany.' Meta description: 'iDEL Therapeutics delivers drugs directly into the cytosol of tumour cells using proprietary shuttle technology — unlocking historically undruggable intracellular targets. Two lead oncology programs advancing to clinic. €9M funded by BiomedVC and NRW.Venture.' Submit the sitemap to Google Search Console on launch day.
SEO
Launch-Day SEO — GlobeNewswire/BioSpace Press Release Links — All Point to idel-tx.com Not idel-therapeutics.com
Score
18
Severity
High
Finding
The GlobeNewswire press release (the primary syndication vehicle for the announcement) links to idel-tx.com. BioSpace, EU-Startups, and VC Magazin all follow the press release. This means all SEO authority from the launch press cycle flows to idel-tx.com — not idel-therapeutics.com. If idel-therapeutics.com is not configured to receive this authority via a proper redirect or canonical tag, the submitted URL is receiving zero SEO benefit from the announcement.
Recommendation
Implement a 301 permanent redirect from idel-therapeutics.com → idel-tx.com today. Then set the page title at idel-tx.com: 'iDEL Therapeutics — Direct Cytosolic Drug Delivery for Oncology | Dortmund, Germany.' Meta description: 'iDEL Therapeutics delivers drugs directly into the cytosol of tumour cells using proprietary shuttle technology — unlocking historically undruggable intracellular targets. Two lead oncology programs advancing to clinic. €9M funded by BiomedVC and NRW.Venture.' Submit the sitemap to Google Search Console on launch day.
Content
KHAN Technology Transfer Fund II (Max Planck Foundation, European Investment Fund) — Prestigious Institutional Backing
Score
28
Severity
Medium
Finding
KHAN Technology Transfer Fund II is backed by the Max Planck Foundation, the European Investment Fund (via InvestEU Equity and ERP-EIF Facility), Akros Pharma, and Thyssen'sche Handelsgesellschaft. The Max Planck and European Investment Fund connections are significant: Max Planck is Europe's most prestigious basic research institution, and the EIF is the EU's primary venture capital backing vehicle. These are not typical VC investors — they signal that iDEL's science has been reviewed and validated by institutions with high scientific standards.
Recommendation
Feature KHAN's backing in the investor section: 'KHAN Technology Transfer Fund II (Max Planck Foundation · European Investment Fund).' The Max Planck association is a tier-1 scientific credibility signal for both pharma BD teams and European government grant bodies — it implies that the underlying science was developed or validated in the Max Planck ecosystem. This context is worth one sentence on the homepage investor section.
Content
KHAN Technology Transfer Fund II (Max Planck Foundation, European Investment Fund) — Prestigious Institutional Backing
Score
28
Severity
Medium
Finding
KHAN Technology Transfer Fund II is backed by the Max Planck Foundation, the European Investment Fund (via InvestEU Equity and ERP-EIF Facility), Akros Pharma, and Thyssen'sche Handelsgesellschaft. The Max Planck and European Investment Fund connections are significant: Max Planck is Europe's most prestigious basic research institution, and the EIF is the EU's primary venture capital backing vehicle. These are not typical VC investors — they signal that iDEL's science has been reviewed and validated by institutions with high scientific standards.
Recommendation
Feature KHAN's backing in the investor section: 'KHAN Technology Transfer Fund II (Max Planck Foundation · European Investment Fund).' The Max Planck association is a tier-1 scientific credibility signal for both pharma BD teams and European government grant bodies — it implies that the underlying science was developed or validated in the Max Planck ecosystem. This context is worth one sentence on the homepage investor section.
Content
KHAN Technology Transfer Fund II (Max Planck Foundation, European Investment Fund) — Prestigious Institutional Backing
Score
28
Severity
Medium
Finding
KHAN Technology Transfer Fund II is backed by the Max Planck Foundation, the European Investment Fund (via InvestEU Equity and ERP-EIF Facility), Akros Pharma, and Thyssen'sche Handelsgesellschaft. The Max Planck and European Investment Fund connections are significant: Max Planck is Europe's most prestigious basic research institution, and the EIF is the EU's primary venture capital backing vehicle. These are not typical VC investors — they signal that iDEL's science has been reviewed and validated by institutions with high scientific standards.
Recommendation
Feature KHAN's backing in the investor section: 'KHAN Technology Transfer Fund II (Max Planck Foundation · European Investment Fund).' The Max Planck association is a tier-1 scientific credibility signal for both pharma BD teams and European government grant bodies — it implies that the underlying science was developed or validated in the Max Planck ecosystem. This context is worth one sentence on the homepage investor section.
Navigation
Pipeline Page — Pre-Clinical Data (Significant Tumour Shrinkage in In Vivo Models) Not Public
Score
30
Severity
Medium
Finding
VC Magazin and European Biotechnology Magazine both reference 'significant tumour shrinkage observed in preclinical in vivo models' for the sdAb programme. This preclinical data is what convinced the initial investors ('diese In-vivo-Daten haben die ersten Investoren zum Staunen gebracht' — these in vivo data astonished the first investors). For a pharma BD audience evaluating partnership opportunities, even a high-level description of the preclinical data package adds credibility.
Recommendation
Add a Pipeline page with: 'IDL-001 (sdAb programme): Preclinical in vivo data demonstrate significant tumour shrinkage. IND-enabling studies planned. Target class: intracellular oncotargets. Modality: single-domain antibody. IDL-002 (mCDC programme): Multi-cancer applicability, no tumour-associated antigen requirement. siRNA proof of concept demonstrated.' This level of disclosure is appropriate for a seed-stage biotech and is required for pharma partnership conversations.
Navigation
Pipeline Page — Pre-Clinical Data (Significant Tumour Shrinkage in In Vivo Models) Not Public
Score
30
Severity
Medium
Finding
VC Magazin and European Biotechnology Magazine both reference 'significant tumour shrinkage observed in preclinical in vivo models' for the sdAb programme. This preclinical data is what convinced the initial investors ('diese In-vivo-Daten haben die ersten Investoren zum Staunen gebracht' — these in vivo data astonished the first investors). For a pharma BD audience evaluating partnership opportunities, even a high-level description of the preclinical data package adds credibility.
Recommendation
Add a Pipeline page with: 'IDL-001 (sdAb programme): Preclinical in vivo data demonstrate significant tumour shrinkage. IND-enabling studies planned. Target class: intracellular oncotargets. Modality: single-domain antibody. IDL-002 (mCDC programme): Multi-cancer applicability, no tumour-associated antigen requirement. siRNA proof of concept demonstrated.' This level of disclosure is appropriate for a seed-stage biotech and is required for pharma partnership conversations.
Navigation
Pipeline Page — Pre-Clinical Data (Significant Tumour Shrinkage in In Vivo Models) Not Public
Score
30
Severity
Medium
Finding
VC Magazin and European Biotechnology Magazine both reference 'significant tumour shrinkage observed in preclinical in vivo models' for the sdAb programme. This preclinical data is what convinced the initial investors ('diese In-vivo-Daten haben die ersten Investoren zum Staunen gebracht' — these in vivo data astonished the first investors). For a pharma BD audience evaluating partnership opportunities, even a high-level description of the preclinical data package adds credibility.
Recommendation
Add a Pipeline page with: 'IDL-001 (sdAb programme): Preclinical in vivo data demonstrate significant tumour shrinkage. IND-enabling studies planned. Target class: intracellular oncotargets. Modality: single-domain antibody. IDL-002 (mCDC programme): Multi-cancer applicability, no tumour-associated antigen requirement. siRNA proof of concept demonstrated.' This level of disclosure is appropriate for a seed-stage biotech and is required for pharma partnership conversations.
Content
Dortmund / NRW Biotech Ecosystem — Regional Identity Not Featured
Score
35
Severity
Low
Finding
iDEL Therapeutics is based at the Biomedizin Zentrum Dortmund — a specialised biomedical research cluster in North Rhine-Westphalia. The NRW ecosystem has produced successful biotech companies (Bayer, BASF's Ludwigshafen is nearby, and the region is home to significant pharma infrastructure). The regional identity may matter for: EU funding (ERDF/NRW structural funds), talent recruitment, and positioning within the German biotech ecosystem.
Recommendation
Add a brief location context to the About section: 'Based at Biomedizin Zentrum Dortmund, North Rhine-Westphalia — in the heart of Germany's leading life sciences region.' Include the NRW.Venture and Gründerfonds Ruhr investor logos with a brief note: 'Proudly supported by NRW.BANK and the Ruhr region's venture ecosystem.' Regional identity builds relationships with local talent, institutions, and the NRW government stakeholders who may provide follow-on grant funding.
Content
Dortmund / NRW Biotech Ecosystem — Regional Identity Not Featured
Score
35
Severity
Low
Finding
iDEL Therapeutics is based at the Biomedizin Zentrum Dortmund — a specialised biomedical research cluster in North Rhine-Westphalia. The NRW ecosystem has produced successful biotech companies (Bayer, BASF's Ludwigshafen is nearby, and the region is home to significant pharma infrastructure). The regional identity may matter for: EU funding (ERDF/NRW structural funds), talent recruitment, and positioning within the German biotech ecosystem.
Recommendation
Add a brief location context to the About section: 'Based at Biomedizin Zentrum Dortmund, North Rhine-Westphalia — in the heart of Germany's leading life sciences region.' Include the NRW.Venture and Gründerfonds Ruhr investor logos with a brief note: 'Proudly supported by NRW.BANK and the Ruhr region's venture ecosystem.' Regional identity builds relationships with local talent, institutions, and the NRW government stakeholders who may provide follow-on grant funding.
Content
Dortmund / NRW Biotech Ecosystem — Regional Identity Not Featured
Score
35
Severity
Low
Finding
iDEL Therapeutics is based at the Biomedizin Zentrum Dortmund — a specialised biomedical research cluster in North Rhine-Westphalia. The NRW ecosystem has produced successful biotech companies (Bayer, BASF's Ludwigshafen is nearby, and the region is home to significant pharma infrastructure). The regional identity may matter for: EU funding (ERDF/NRW structural funds), talent recruitment, and positioning within the German biotech ecosystem.
Recommendation
Add a brief location context to the About section: 'Based at Biomedizin Zentrum Dortmund, North Rhine-Westphalia — in the heart of Germany's leading life sciences region.' Include the NRW.Venture and Gründerfonds Ruhr investor logos with a brief note: 'Proudly supported by NRW.BANK and the Ruhr region's venture ecosystem.' Regional identity builds relationships with local talent, institutions, and the NRW government stakeholders who may provide follow-on grant funding.
Brand
Wunder-Shuttle' (Wonder Shuttle) — Vivid German Media Framing Not Used in English Materials
Score
38
Severity
Low
Finding
European Biotechnology Magazine titled their article 'Delivering drugs into cells: Seed funding for German iDEL and its wonder shuttle' — calling the technology a 'Wunder-Shuttle' (wonder shuttle) in the German-language coverage. This phrase is memorable, evocative, and scientifically descriptive simultaneously. If the English-language website and press materials use only technical language ('synthetic shuttle technology platform'), the memorable analogy that sticks in journalists' and investors' minds is being left in German-language trade press.
Recommendation
Consider using 'shuttle technology' with the 'wonder shuttle' framing as a secondary descriptor in English materials: 'iDEL's cytosolic shuttle technology — the 'wonder shuttle' of cancer drug delivery.' The phrase works because it communicates: small, precise, and gets directly to where it needs to go. In a crowded oncology drug delivery field, a memorable name for the mechanism helps differentiate from other delivery technology platforms in investor and BD conversations.
Brand
Wunder-Shuttle' (Wonder Shuttle) — Vivid German Media Framing Not Used in English Materials
Score
38
Severity
Low
Finding
European Biotechnology Magazine titled their article 'Delivering drugs into cells: Seed funding for German iDEL and its wonder shuttle' — calling the technology a 'Wunder-Shuttle' (wonder shuttle) in the German-language coverage. This phrase is memorable, evocative, and scientifically descriptive simultaneously. If the English-language website and press materials use only technical language ('synthetic shuttle technology platform'), the memorable analogy that sticks in journalists' and investors' minds is being left in German-language trade press.
Recommendation
Consider using 'shuttle technology' with the 'wonder shuttle' framing as a secondary descriptor in English materials: 'iDEL's cytosolic shuttle technology — the 'wonder shuttle' of cancer drug delivery.' The phrase works because it communicates: small, precise, and gets directly to where it needs to go. In a crowded oncology drug delivery field, a memorable name for the mechanism helps differentiate from other delivery technology platforms in investor and BD conversations.
Brand
Wunder-Shuttle' (Wonder Shuttle) — Vivid German Media Framing Not Used in English Materials
Score
38
Severity
Low
Finding
European Biotechnology Magazine titled their article 'Delivering drugs into cells: Seed funding for German iDEL and its wonder shuttle' — calling the technology a 'Wunder-Shuttle' (wonder shuttle) in the German-language coverage. This phrase is memorable, evocative, and scientifically descriptive simultaneously. If the English-language website and press materials use only technical language ('synthetic shuttle technology platform'), the memorable analogy that sticks in journalists' and investors' minds is being left in German-language trade press.
Recommendation
Consider using 'shuttle technology' with the 'wonder shuttle' framing as a secondary descriptor in English materials: 'iDEL's cytosolic shuttle technology — the 'wonder shuttle' of cancer drug delivery.' The phrase works because it communicates: small, precise, and gets directly to where it needs to go. In a crowded oncology drug delivery field, a memorable name for the mechanism helps differentiate from other delivery technology platforms in investor and BD conversations.